Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | RNASEH1 | O60930 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15956955 | 0.86 | RNASEH1 (0.50) | PLA2G10PLA2G2ARNASEH1DAOKMT2A | |
| SCHEMBL15964741 | 0.85 | SRD5A2 (0.40) | PLA2G10PLA2G2AGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL15956818 | 0.84 | RNASEH1 (0.49) | PLA2G10PLA2G2ARNASEH1DAOKMT2A | |
| SCHEMBL15964821 | 0.83 | NR3C2 (0.45) | DAOTAAR1KDM4E | |
| SCHEMBL19037422 | 0.83 | LMNA (0.49) | RNASEH1DAOKMT2AGAAALDH1A1 | |
| SCHEMBL15964837 | 0.82 | HCAR2 (0.46) | DAOHCAR2 | |
| SCHEMBL18419869 | 0.80 | KMT2A (0.43) | RNASEH1DAOKMT2AGAAMAPT | |
| SCHEMBL18377480 | 0.80 | BRD4 (0.48) | RNASEH1DAOKMT2AGAAALDH1A1 | |
| SCHEMBL15956900 | 0.79 | SMN1; SMN2 (0.52) | RNASEH1KMT2AMAPTALDH1A1TSHR | |
| SCHEMBL20344663 | 0.79 | RNASEH1 (0.41) | PLA2G10PLA2G2ARNASEH1DAOKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528915-A | Compounds for inhibiting apoptosis and methods of making the same | 中国科学院上海有机化学研究所 | 2025-02-28 | — | — | CN | disclosed |
| CN-115806557-B | Compounds for inhibiting apoptosis and methods of making the same | 中国科学院上海有机化学研究所 | 2025-02-14 | — | — | CN | disclosed |
| US-20250049812-A1 | Compounds that Inhibit Necroptosis and Their Preparation Methods | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4403557-A1 | COMPOUND THAT INHIBITS PROGRAMMED CELL NECROSIS, AND PREPARATION METHOD THEREFOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2024-07-24 | — | — | EP | disclosed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3788044-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2023040818-A1 | COMPOUND THAT INHIBITS PROGRAMMED CELL NECROSIS, AND PREPARATION METHOD THEREFOR | 中国科学院上海有机化学研究所 | 2023-03-23 | — | — | WO | disclosed |
| CN-115806557-A | Compound for inhibiting programmed cell death and preparation method thereof | 中国科学院上海有机化学研究所 | 2023-03-17 | — | — | CN | disclosed |
| EP-3375780-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| EP-3508484-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| EP-3342771-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2018-07-04 | — | — | EP | disclosed |
| EP-2956452-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-03-21 | — | — | EP | disclosed |
| WO-2017109724-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| WO-2014125444-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-08-21 | — | — | WO | disclosed |
| US-7812041-B2 | Heterocyclic NF-κB inhibitors | 4SC AG (DE) | 2010-10-12 | — | — | US | disclosed |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | 4SC AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, NFKB2, NFRKB | PLA2G10 4569/4885PLA2G2A 4792/4885RNASEH1 3686/4885 |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | NFKBIA, NFKB2, NFRKB | PLA2G10 4662/4885PLA2G2A 4813/4885RNASEH1 3602/4885 |
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | PLA2G10 3694/4885PLA2G2A 4192/4885RNASEH1 1267/4885 |
| US-20250049812-A1 | Compounds that Inhibit Necroptosis and Their Preparation Methods | RIPK1, RIPK3, RIPK4 | PLA2G10 2930/4885PLA2G2A 3521/4885RNASEH1 706/4885 |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFKB2, NFRKB | PLA2G10 4620/4885PLA2G2A 4809/4885RNASEH1 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.